AGTR1 and hypertensive disorder: For example, the CYT006-AngGb vaccine, which targets Ang II, has shown promising results in a phase II clinical trial by reducing BP in patients with mild to moderate hypertension without causing serious adverse events.527 The ATRQβ-001 vaccine, which targets the AT1R, has shown success in lowering BP in Ang II-induced hypertensive mice and SHR.528 However, more further studies on antihypertensive vaccines are warranted.